Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

Stocks like Welspun Corp, SBI Life Insurance Company, Oil and Natural Gas Corporation, NTPC, Waterbase, Shree Cement, Refex ...

Starbucks said on Monday it would eliminate 1,100 corporate roles as CEO Brian Niccol pushes ahead with his turnaround ...